<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162678</url>
  </required_header>
  <id_info>
    <org_study_id>2N-19-3</org_study_id>
    <secondary_id>NCI-2019-05861</secondary_id>
    <secondary_id>2N-19-3</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT04162678</nct_id>
  </id_info>
  <brief_title>Fluid Biopsy for the Diagnosis of Lung Cancer</brief_title>
  <official_title>Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung
      cancer. Studying blood samples in the laboratory may help doctors develop a blood test for
      lung cancer in the future and provide a better way to screen patients for lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To estimate the sensitivity and specificity of the fluid biopsy in establishing a
      diagnosis of bronchogenic carcinoma.

      SECONDARY OBJECTIVES:

      I. To determine the accuracy of determination of the histologic subtype of bronchogenic lung
      cancer.

      II. To determine the relative contribution of cell based high definition circulating tumor
      cell assay (HD-CTC) and imaging mass cytometry (IMC) and plasma based circulating tumor
      deoxyribonucleic acid (ctDNA) assays in determination of diagnosis and histologic subtype.

      OUTLINE:

      Patients undergo collection of blood samples on day 1 for analysis via high definition
      (HD)-single cell analysis (SCA) fluid biopsy. Medical charts of patients are reviewed at 3
      months post-biopsy or computed tomography (CT) screening.

      After completion of study, patients are followed for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">January 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical diagnosis of lung cancer</measure>
    <time_frame>Within 90 days of tissue biopsy</time_frame>
    <description>Descriptive statistics including sensitivity, specificity, positive, and negative predictive value will be tabulated.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (blood collection via fluid biopsy, lab analysis)</arm_group_label>
    <description>Patients undergo collection of blood samples on day 1 for analysis via HD-SCA fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or CT screening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood via HD-SCA fluid biopsy</description>
    <arm_group_label>Diagnostic (blood collection via fluid biopsy, lab analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (blood collection via fluid biopsy, lab analysis)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liquid Biopsy</intervention_name>
    <description>Undergo collection of blood via HD-SCA fluid biopsy</description>
    <arm_group_label>Diagnostic (blood collection via fluid biopsy, lab analysis)</arm_group_label>
    <other_name>Plasma Biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical Chart Review</intervention_name>
    <description>Review of medical chart</description>
    <arm_group_label>Diagnostic (blood collection via fluid biopsy, lab analysis)</arm_group_label>
    <other_name>Chart Review</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing a biopsy or CT screening for lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo a diagnostic biopsy for possible lung cancer or

          -  Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet
             undergone treatment or

          -  Planning or completed in the last 2 weeks a CT lung cancer screen

          -  Ability to understand and the willingness to sign a written informed consent

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
             the study

          -  Known other solid tumor malignancy other than lung cancer requiring ongoing active
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge J Nieva</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Grace Facio, RN</last_name>
    <phone>323-409-7027</phone>
    <email>GFacio@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace M. Facio, RN</last_name>
      <phone>323-409-7027</phone>
      <email>gfacio@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge J. Nieva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace M. Facio, RN</last_name>
      <phone>323-409-7027</phone>
      <email>gfacio@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge J. Nieva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 11, 2019</study_first_submitted>
  <study_first_submitted_qc>November 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

